NovoCure Limited
| Company Name | NovoCure Limited |
| Stock Symbol | NVCR |
| Status | 1 |
The Firm announces an investigation on behalf of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR) investors concerning the Company and its officers’ possible violations of federal securities laws. GPM is preparing a lawsuit on behalf of NovoCure investors.
NovoCure develops and commercializes oncology treatments. The Company’s lead approved product for the treatment of solid tumor Optune is used for monotherapy treatment in adult patients with glioblastoma brain cancer.
On July 28, 2016, NovoCure announced that its new Optune prescriptions fell to 657 in 2Q from 755 in 1Q. Asaf Danziger, Chief Executive Officer of Novocure stated that “[w]hile barriers to full adoption remain, I am optimistic we will overcome the challenges inherent in bringing a completely new therapy into widespread clinical use.”
On this news, NovoCure’s stock fell nearly 30% on July 28, 2016 to close at $8.09 per share.
If you purchased NovoCure securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224 or by email to shareholders@glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
Submit Your Information
If you suffered a loss on your NovoCure Limited investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.